Author

Maria Gonzalez-Cao

Institutions: Instituto Oncológico Dr. Rosell, Hospital Universitario Dexeus

Observed institutions: Instituto Oncológico Dr. Rosell, Hospital Universitario Dexeus

ORCID: 0000-0003-3791-540X

Observed ORCID: 0000-0003-3791-540X

OpenAlex ID: A5111338059

The combination of checkpoint immunotherapy and targeted therapy in cancer

2017 · Niki Karachaliou, Maria Gonzalez-Cao, et al. · Annals of Translational Medicine · 71

Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma

2024 · Paolo A. Ascierto, Mario Mandalà, et al. · NEJM Evidence · 19

Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial

2026 · Vanesa Gregorc, Margarita Majem, et al. · The Lancet Oncology · 14

Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF -Altered Solid Tumors or NRAS -Mutant Melanoma

2026 · Valentina Gambardella, Meredith McKean, et al. · JCO oncology advances. · 3

Phase Ib of repotrectinib plus osimertinib in patients with EGFR–mutated advanced non–small cell lung cancer

2026 · Andres Aguilar, Manuel Cobo, et al. · Lung Cancer

Works count: 5

Citation count: 107

H-index: 3

I10-index: 3